BridgeBio’s $250M offering; ViiV’s PhI data for ultra-long-acting HIV treatment

Plus, news about Viking Ther­a­peu­tics, Ar­cutis Bio­ther­a­peu­tics, Akari and Peak Bio:

Bridge­Bio’s stock sale: The com­pa­ny an­nounced plans to raise $250 mil­lion the same day that Bay­er said it is pur­chas­ing the Eu­ro­pean rights to aco­ramidis, Bridge­Bio’s AT­TR amy­loi­do­sis with car­diomy­opa­thy treat­ment can­di­date. Bridge­Bio’s shares $BBIO were down 7% Tues­day morn­ing. — Lei Lei Wu

Vi­iV Health­care touts PhI HIV treat­ment da­ta: The com­pa­ny’s ul­tra-long-act­ing for­mu­la­tion of the an­ti­retro­vi­ral cabote­gravir can be in­ject­ed at in­ter­vals of at least four months, per da­ta from the Phase I test. Cabote­gravir is one of the ac­tive in­gre­di­ents in Cabe­nu­va. HIV treat­ment shots are cur­rent­ly giv­en once a month or every oth­er month. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.